Rapport Therapeutics, Common Stock Analysis
| RAPP Stock | 24.00 1.16 5.08% |
Rapport Therapeutics, Common is undervalued with Real Value of 27.53 and Target Price of 35.0. The main objective of Rapport Therapeutics, stock analysis is to determine its intrinsic value, which is an estimate of what Rapport Therapeutics, Common is worth, separate from its market price. There are two main types of Rapport Therapeutics,'s stock analysis: fundamental analysis and technical analysis.
The Rapport Therapeutics, stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Rapport Therapeutics, is usually not traded on Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day. Rapport Stock trading window is adjusted to America/New York timezone.
Rapport |
Rapport Stock Analysis Notes
About 93.0% of the company shares are owned by institutional investors. The book value of Rapport Therapeutics, was at this time reported as 9.21. The company recorded a loss per share of 1.72. Rapport Therapeutics, had not issued any dividends in recent years. To find out more about Rapport Therapeutics, Common contact Abraham MBA at 857 321 8020 or learn more at https://www.rapportrx.com.Rapport Therapeutics, Investment Alerts
| Rapport Therapeutics, had very high historical volatility over the last 90 days | |
| Net Loss for the year was (34.79 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Rapport Therapeutics, generates negative cash flow from operations | |
| Rapport Therapeutics, has a poor financial position based on the latest SEC disclosures | |
| Over 93.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: APRIL Group Awards Scholarships to 250 High School and Vocational Students across Its Five Operational Districts in Pangkalan Kerinci, Pelalawan in Indonesia |
Rapport Largest EPS Surprises
Earnings surprises can significantly impact Rapport Therapeutics,'s stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-08 | 2024-06-30 | -0.68 | -1.7 | -1.02 | 150 |
Rapport Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 762.25 M.Rapport Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.22) | (0.24) | |
| Return On Capital Employed | (0.25) | (0.26) | |
| Return On Assets | (0.22) | (0.24) | |
| Return On Equity | (0.25) | (0.26) |
Technical Drivers
As of the 2nd of December, Rapport Therapeutics, holds the Semi Deviation of 4.66, coefficient of variation of 1641.27, and Risk Adjusted Performance of 0.0552. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Rapport Therapeutics,, as well as the relationship between them.Rapport Therapeutics, Price Movement Analysis
The output start index for this execution was twenty-seven with a total number of output elements of thirty-four. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Rapport Therapeutics, middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Rapport Therapeutics,. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Rapport Therapeutics, Predictive Daily Indicators
Rapport Therapeutics, intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Rapport Therapeutics, stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 5045.57 | |||
| Daily Balance Of Power | 0.8992 | |||
| Rate Of Daily Change | 1.05 | |||
| Day Median Price | 23.53 | |||
| Day Typical Price | 23.68 | |||
| Price Action Indicator | 1.05 | |||
| Period Momentum Indicator | 1.16 |
Rapport Therapeutics, Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 13th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 7th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 18th of October 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
8K | 8th of August 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 26th of July 2024 Other Reports | ViewVerify | |
13A | 10th of July 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Rapport Therapeutics, Forecast Models
Rapport Therapeutics,'s time-series forecasting models are one of many Rapport Therapeutics,'s stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Rapport Therapeutics,'s historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Rapport Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Rapport Therapeutics, prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Rapport shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Rapport Therapeutics,. By using and applying Rapport Stock analysis, traders can create a robust methodology for identifying Rapport entry and exit points for their positions.
| Last Reported | Projected for Next Year |
Current Rapport Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Rapport analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Rapport analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 35.0 | Strong Buy | 4 | Odds |
Most Rapport analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Rapport stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Rapport Therapeutics,, talking to its executives and customers, or listening to Rapport conference calls.
Rapport Stock Analysis Indicators
Rapport Therapeutics, Common stock analysis indicators help investors evaluate how Rapport Therapeutics, stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Rapport Therapeutics, shares will generate the highest return on investment. By understating and applying Rapport Therapeutics, stock analysis, traders can identify Rapport Therapeutics, position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 31.2 M | |
| Common Stock Shares Outstanding | 164.4 M | |
| Total Stockholder Equity | 140.9 M | |
| Tax Provision | 10000.00 | |
| Property Plant And Equipment Net | 4 M | |
| Cash And Short Term Investments | 147.6 M | |
| Cash | 70.2 M | |
| Accounts Payable | 2.5 M | |
| Net Debt | -68 M | |
| 50 Day M A | 21.236 | |
| Total Current Liabilities | 8.8 M | |
| Other Operating Expenses | 36.2 M | |
| Non Current Assets Total | 4.6 M | |
| Non Currrent Assets Other | 551 K | |
| Stock Based Compensation | 3.5 M |
Additional Tools for Rapport Stock Analysis
When running Rapport Therapeutics,'s price analysis, check to measure Rapport Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rapport Therapeutics, is operating at the current time. Most of Rapport Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Rapport Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rapport Therapeutics,'s price. Additionally, you may evaluate how the addition of Rapport Therapeutics, to your portfolios can decrease your overall portfolio volatility.